These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 17707907

  • 1. Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.
    Santana-Davila R, Holtan SG, Dewald GW, Ketterling RP, Knudson RA, Hanson CA, Steensma DP, Tefferi A.
    Leuk Res; 2008 Mar; 32(3):407-11. PubMed ID: 17707907
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of del(20q) in patients with hematological malignancies.
    Brezinová J, Zemanová Z, Ransdorfová S, Sindelárová L, Sisková M, Neuwirtová R, Cermák J, Michalová K.
    Cancer Genet Cytogenet; 2005 Jul 15; 160(2):188-92. PubMed ID: 15993278
    [Abstract] [Full Text] [Related]

  • 3. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD, Chen D, Hanson CA, Porrata L, Tefferi A, Steensma DP.
    Am J Hematol; 2008 Sep 15; 83(9):708-13. PubMed ID: 18634051
    [Abstract] [Full Text] [Related]

  • 4. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
    Giagounidis AA, Germing U, Aul C.
    Clin Cancer Res; 2006 Jan 01; 12(1):5-10. PubMed ID: 16397017
    [Abstract] [Full Text] [Related]

  • 5. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A.
    Clin Lymphoma Myeloma; 2009 Jan 01; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [Abstract] [Full Text] [Related]

  • 6. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD.
    J Clin Oncol; 2006 Jun 01; 24(16):2576-82. PubMed ID: 16735711
    [Abstract] [Full Text] [Related]

  • 7. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
    Swolin B, Rödjer S, Westin J.
    Ann Hematol; 2008 Jun 01; 87(6):467-74. PubMed ID: 18351338
    [Abstract] [Full Text] [Related]

  • 8. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C, Bacher U, Tiu R, Maciejewski JP, List A.
    Cancer Genet Cytogenet; 2008 Dec 01; 187(2):101-11. PubMed ID: 19027491
    [Abstract] [Full Text] [Related]

  • 9. Deletion (11)(q13) as the sole anomaly in myeloid malignancies: four new cases and a short review.
    Panani AD, Pappa V, Papageorgiou S, Stamatelli F, Raptis SA.
    Ann Hematol; 2004 Mar 01; 83(3):153-5. PubMed ID: 15064863
    [Abstract] [Full Text] [Related]

  • 10. Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients.
    Yilmaz Z, Sahin FI, Kizilkilic E, Karakus S, Boga C, Ozdogu H.
    Clin Exp Med; 2005 Jul 01; 5(2):55-9. PubMed ID: 16096854
    [Abstract] [Full Text] [Related]

  • 11. Deletions of chromosome 5 in malignant myeloid disorders.
    Le Beau MM.
    Cancer Surv; 1992 Jul 01; 15():143-59. PubMed ID: 1451109
    [Abstract] [Full Text] [Related]

  • 12. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
    Santana-Davila R, Tefferi A, Holtan SG, Ketterling RP, Dewald GW, Knudson RA, Steensma DP, Chen D, Hoyer JD, Hanson CA.
    Leuk Res; 2008 Dec 01; 32(12):1927-30. PubMed ID: 18538839
    [Abstract] [Full Text] [Related]

  • 13. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia.
    Trost D, Hildebrandt B, Beier M, Müller N, Germing U, Royer-Pokora B.
    Cancer Genet Cytogenet; 2006 Feb 01; 165(1):51-63. PubMed ID: 16490597
    [Abstract] [Full Text] [Related]

  • 14. Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodyplastic syndromes and acute myeloid leukemia.
    Royer-Pokora B, Trost D, Müller N, Hildebrandt B, Germing U, Beier M.
    Cancer Genet Cytogenet; 2006 May 01; 167(1):66-9. PubMed ID: 16682289
    [Abstract] [Full Text] [Related]

  • 15. Molecular diagnosis of the 5q deletion in malignant myeloid disorders.
    Boultwood J.
    Methods Mol Med; 1996 May 01; 6():91-103. PubMed ID: 21380700
    [Abstract] [Full Text] [Related]

  • 16. Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders.
    Zhang LJ, Shin ES, Yu ZX, Li SB.
    Chin Med J (Engl); 2007 Nov 20; 120(22):2002-5. PubMed ID: 18067786
    [Abstract] [Full Text] [Related]

  • 17. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, del Rey M, Arranz E, Ramiro S, Font P, González O, Renedo M, Cervera J, Such E, Sanz GF, Luño E, Sanzo C, González M, Calasanz MJ, Mayans J, García-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yañez L, Muruzabal MJ, Gómez-Beltrán E, Andreu R, León P, Gómez V, Sanz A, Casasola N, Moreno E, Alegre A, Martín ML, Pedro C, Serrano S, Florensa L, Solé F.
    Haematologica; 2008 Jul 20; 93(7):1001-8. PubMed ID: 18591625
    [Abstract] [Full Text] [Related]

  • 18. Cytogenetic polyclonality in hematologic malignancies.
    Johansson B, Billström R, Broberg K, Fioretos T, Nilsson PG, Ahlgren T, Malm C, Samuelsson BO, Mitelman F.
    Genes Chromosomes Cancer; 1999 Mar 20; 24(3):222-9. PubMed ID: 10451702
    [Abstract] [Full Text] [Related]

  • 19. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
    Jaju RJ, Haas OA, Neat M, Harbott J, Saha V, Boultwood J, Brown JM, Pirc-Danoewinata H, Krings BW, Müller U, Morris SW, Wainscoat JS, Kearney L.
    Blood; 1999 Jul 15; 94(2):773-80. PubMed ID: 10397745
    [Abstract] [Full Text] [Related]

  • 20. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
    Giagounidis AA, Haase S, Heinsch M, Göhring G, Schlegelberger B, Aul C.
    Ann Hematol; 2007 Feb 15; 86(2):133-7. PubMed ID: 17111142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.